FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 539 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 Bride Cancels Engagement Photos To Share Special Dance With Terminal Dad. April 19, 2019 New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... December 5, 2019 NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... November 18, 2025 Load more HOT NEWS Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... Lung Cancer Treatment Research Enters a New Era Embedding research integrity at the core of our science
